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reactive oxygen species (roS) are considered to be important signalling molecules controlling many 
platelet functions. roS production has been shown to be augmented by platelet activation, however, plas-
minogen (Pg) has not been studied in the context of modulating intraplatelet roS levels. The aim of this 
study was to investigate the ability of different Pg forms to affect platelet metabolic activity/survival and 
intracellular roS production in resting and activated platelets. Platelets isolated from donor plasma were 
pre-treated with Glu- or Lys-Pg (1.2 µM) and activated by thrombin (1.0 NIH unit/ml) or collagen (1.25 mg/
ml). mTT assay was adapted to estimate total mitochondrial dehydrogenase activity, while intracellular roS 
levels were monitored with the use of h2DCF-DA probe by flow cytometry. Lys-Pg was shown to slightly, but 
significantly, mitigate MTT reduction (P < 0.05 vs. control platelets). Two-fold elevation in metabolic activity 
of platelets stimulated by thrombin as compared to untreated cells was observed. however, this activation 
was less exhibi ted in the case of platelets pre-incubated with either Glu- of Lys-Pg, with a predominant effect 
of Lys-Pg. Unlike thrombin, collagen treatment dramatically suppressed metabolic activity of platelets by 
60% compared to control (P < 0.05). Glu- or Lys-Pg pre-incubation had no effects on the activity of collagen-
stimulated platelets. Two subpopulations of platelets were observed with distinct characteristics of intracel-
lular roS formation. elevated roS production was demonstrated in these populations of both thrombin- and 
collagen-treated platelets. Pg (Lys-form to greater extent) enhanced intracellular roS generation in throm-
bin-stimulated platelets. These findings suggest that augmented ROS generation within platelets pre-treated 
with Pg followed by their stimulation may result in down-regulation of their survival and functional activity. 
This study adds to our understanding one more possible mechanism of Pg impact on the platelet function.
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P latelets are multifunctional enucleated cell fragments, playing crucial roles in blood clotting, immune response, inflammation, 
cell proliferation and apoptosis, tissue remodelling 
and wound healing [1]. The central event in platelet 
physiology is their activation that includes a complex 
interplay of adhesion and signaling molecules. It is 
generally accepted that platelet activation is induced 
by collagen or soluble platelet agonists that bind G-
protein-coupled receptors, resulting in the activation 
of platelet adhesion receptors, mainly the integrin 
αIIbβ3, which mediates platelet secretion, adhesion, 
and aggregation, which are energy-consuming pro-
cesses [2]. These cells have a greater rate of ATP 
turnover than resting mammalian muscle cells, sug-
gesting they are fairly metabolically active. Resting 
platelets have been shown to derive approximately 
60% of their ATP from glycolysis, whereas aerobic 
respiration accounts for 30-40% of energy basally. 
However, during platelet activation and secretion, 
the rate of both glycolysis and aerobic respiration in-
crease significantly to accommodate escalated ener­
gy demand [3].
During platelet activation induced by various 
agonists or upon ligation of platelet receptors 
through subendothelial matrix proteins, intracel-
lular reactive oxygen species (ROS) are generated, 
further amplifying platelet activation response. Re-
cent studies have suggested that several ROS, such 
as superoxide O2•−, hydroxyl HO•, hydrogen peroxi-
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de H2O2 and others , play a role as secondary mes-
sengers in platelet signal transduction, activation, 
degranulation, adhesion, and aggregation [4, 5]. 
Seve ral sources of ROS in activated platelets have 
been identified. One of the main source of ROS is 
NADPH oxidase (NOX) isoforms, which are activat-
ed through the platelet collagen receptor, GPVI, and 
protease-activated receptors (PAR-1 and -4) evoked 
by thrombin. Other sources of intraplatelet ROS are 
cyclooxygenase and 12-lipoxygenase (arachidonic 
acid metabolism), glutathione cycle, and xanthine 
oxidase. Accumulating evidence suggests that mito-
chondria regulate platelet activation beyond simply 
providing ATP. Platelets activated by thrombin are 
characterized with mitochondrial oxidative burst and 
electron leakage from the respiratory chain, while 
the formation of platelet aggregates is associated 
with the burst of H2O2 [6]. The formation of ROS 
occurs when unpaired electrons escape the electron 
transport chain and react with molecular oxygen, 
generating ROS. Production of mitochondrial ROS is 
closely linked with changes in mitochondrial mem-
brane potential, while increase in membrane poten-
tial (hyperpolarization) can augment the reduction 
of the electron transport chain resulting in the leak 
of electrons out of the chain and subsequent O2•− 
generation. Complexes I, II, and III of the electron 
transport chain are the major potential loci for ROS 
generation [7]. 
It has been shown that ROS are involved in 
regulation of conformational state of the key protein 
receptors responsible for ligand-receptor interactions 
during platelet aggregation. ROS induce changes in 
intraplatelet Ca2+ homeostasis, thus maybe serve as 
secondary messengers in thrombin- or collagen-acti-
vated platelets. However, other potential mechanism 
of how ROS regulate signaling pathways is through 
oxidation of cysteine residues of signaling proteins. 
Several studies indicate ROS to regulate the activa-
tion of integrin αIIbβ3 and the subsequent aggrega-
tion of platelets and thrombus growth [8, 9]. On the 
other hand, ROS imbalance could potentially impact 
platelet function in either reversible or irreversible 
ways. An increase in intracellular ROS beyond a 
certain threshold level will harm activity of platelets 
and down-regulate their adhesive function [10]. Ear-
lier data indicate that mitochondrial ROS is involved 
in the apoptotic process [11]. Understanding these 
metabolic changes is important in designing new ap-
proaches to modulate platelet function, and assessing 
the impact of current interventions for cardiovascu-
lar diseases, cancer or other pathologies associated 
with abnormal platelet bioenergetic capacity.
Pg is a circulating non-active zymogen of plas-
min (Pm) (EC 3.4.21.7), which is best known for its 
function as a key enzyme of the fibrinolytic cascade 
[12]. There are two forms of Pg, the native predomi-
nant Glu-Pg and the intermediate form Lys-Pg, 
which is formed by partial cleavage of Glu-Pg on the 
fibrin matrix or cell surface. It is important to note 
that Lys-Pg represents an open conformation that is 
more readily converted into Pm than Glu-form [13]. 
Pg/Pm can bind to various cells to regulate their 
functional activity [14]. Our recent findings add to 
a growing literature that Pg/Pm system has a num-
ber of crucial functions beyond fibrinolysis. We have 
earlier shown that Lys-Pg, but not native proenzyme, 
is able to inhibit agonist-induced platelet aggrega-
tion [15]. In order to verify possible mechanisms of 
such effects, it has been demonstrated that Lys­Pg 
interferes agonist-stimulated reconstruction of actin 
cytoskeleton [16] and suppresses α­granule release 
[17]. However, how Glu- or Lys-isoforms of Pg might 
alter the key intraplatelet signaling events remains 
still unknown. Hence, the aim of the present study 
was to investigate the ability of different Pg forms to 
affect metabolic activity (as a measure of cell sur-
vival) and intracellular ROS production in resting 
and activated platelets.
materials and methods
reagents and proteins. 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (tetra-
zolium dye MTT), H2DCF-DA, bovine serum al-
bumin (BSA), α­thrombin (EC 3.4.21.5), glucose, 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), dimethyl sulfoxide (DMSO), and other 
chemicals and reagents were from Sigma Aldrich 
(USA) except for those specified.
Glu­Pg from fresh human plasma was purified 
by affine chromatography on Lys­sepharose 4B (GE 
Healthcare Life Sciences, USA) as described else-
where [18]. Human Lys-Pg was isolated from the fro-
zen human plasma Cohn fraction III paste [19, 20]. 
Both forms of Pg were of electrophoretic purity and 
did not exhibit spontaneous proteolytic activity.
Platelet preparation and experimental design. 
Blood from five normal drug-free healthy male 
volun teers was collected by phlebotomy without 
vacuum into 3.2% sodium citrate as anticoagulant in 
polypropylene tubes. Blood was centrifuged at 160 g 
for 20 min at room temperature for platelet rich 
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plasma (PRP) isolation. Then, washed platelets were 
obtained from PRP by gel­filtration on the 10 ml Se-
pharose CL-2B column (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden). HEPES buffer (20 mМ 
НЕРЕS, рН 6.8, 137 mМ NaCl, 4 mM KCl, 0.2 mM 
MgCl2, 0.2% glucose and 0.2% BSA) was used for 
the elution of platelets in the void volume. All assays 
were performed within 60-80 min after platelet col-
lection. To check functional response on agonist’s 
action, platelet aggregation was monitored in a Solar 
AT-02 light transmitting aggregometer (Republic of 
Belarus) using washed platelets adjusted to 107 cells/
ml under constant stirring at 37 °C.
To estimate effects of Pg isoforms on the 
studied parameters, platelets were preincubated with 
Glu­ or Lys­Pg (1.2 µM final concentration) for 3 min 
at 37 °C. For platelet activation, thrombin (1.0 NIH 
units/ml) or collagen (Tehnologiia Standart, Russian 
Federation) (1.25 mg/ml) were added to untreated or 
Pg-pretreated platelets for 5 min. After treatment, 
platelets were immediately washed from studied pro-
teins by two-time centrifugation (1,000 g for 10 min 
at 25 °C) in phosphate buffered saline (PBS). Non­
treated platelets were processed in the same man-
ner except physiological saline was added as vehicle 
(resting control). 
mTT-assay. The MTT assay is based on the 
intracellular conversion of a tetrazolium, which is 
reduced to purple formazan by NAD(P)H-depen-
dent mitochondrial dehydrogenases indicating nor-
mal cell metabolism [21]. Intact and treated platelets 
were sedimented and the pellets were resuspended in 
MTT solution (1 mg/ml PBS). Platelets resuspended 
in pure PBS were used as a negative control. Plate-
lets were allowed to reduce MTT for 60 min at 37 °C 
with MTT, and then were washed from the MTT 
residues by the centrifugation at 16,000 g for 20 min 
at 4 °C. Supernatants were discarded, and then intra-
cellular water-insoluble formazan crystals were dis-
solved in 1 ml DMSO. Resultant absorbance values 
were measured with the use of SF-2000 spectropho-
tometer (Russia Federation) at λ = 500 and 630 nm. 
Each tested sample was measured in triplicate. The 
results were expressed as Δ(500­630 nm).
Flow cytometry (intraplatelet roS measure-
ments). H2DCF­DA is currently used in flow cy-
tometry analyses for direct and reliable relative 
quantification of intracellular ROS. After cyto-
solic hydrolysis, H2DCF-DA can be oxidized into 
2′,7′­dichlorofluorescein (DCF), which fluoresces at 
520 nm. One of the main advantages of this tech-
nique is that it allows the rapid detection of ROS, 
so that even short-lived oxidative imbalance can be 
measu red [22].
Platelets were incubated with the studied pro-
teins as described above, washed and loaded with 
12.5 µM H2DCF-DA in PBS. After 30 min incu-
bation at 37 °C in the dark chamber, samples were 
diluted with 5-fold ice-cold PBS and kept on ice 
until analyzed. All flow cytometry analysis was 
performed on a Coulter Epics XL device (Beckman 
Coulter, USA) via FL2 channel (575 nm). Popula-
tion of untreated (control) platelets was chosen 
for threshold value setting. DCF-positive plate-
let population was gated separately on the basis of 
side-scattered light (SSC). For all samples, at least 
15,000 events were analyzed. The measurement of 
cytometric parameters in each group of platelets was 
done in duplicate, and the mean value was calculated 
based on the values obtained from all donors. For all 
ROS experiments, median DCF fluorescence inten-
sity values were recorded and expressed as arbitrary 
units. The results were analyzed and presented using 
“FCS Express V3” software system (De Novo Soft-
ware, USA).
Statistical analysis. All results are given as 
mean and standard error of mean (m ± m). A t-test 
or Mann­Whitney’s U­test were used to calculate P 
value. A P value less than 0.05 (P < 0.05) was con-
sidered significant.
results and discussion
MTT-test, which is conventionally utilized 
for evaluation of viability or proliferative capabili-
ty of nucleated cells, was adopted for assessment 
of changes in metabolic activity of platelets treated 
with the studied proteins. The results of these measu-
rements are depicted in Fig. 1.
It was demonstrated that washed human plate-
lets were able to reduce a tetrazolium salt by their 
mitochondrial dehydrogenases. Although the effect 
of Glu-Pg (1.2 µM) on platelet metabolic activity was 
minimal, the same concentration of Lys-Pg mitigated 
MTT reduction slightly, but in a statistically signifi-
cant way. Two-fold elevation in formazan level in 
platelets activated by thrombin (1.0 NIH units/ml) 
as compared to untreated cells was observed after 
60 min incubation with tetrazolium salt. However, 
this activation was less exhibited in the case of plate-
lets preincubated with either Glu- of Lys-Pg, with 
a predominant effect of Lys­Pg. Unlike thrombin, 
collagen treatment suppressed metabolic activity 
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Fig. 1. Effects of Glu- or Lys-plasminogen on meta-
bolic activity of resting and activated platelets (by 
mTT-test results): Ctrl – control, Thr – thrombin, 


















of platelets by 60% compared to control (P < 0.05). 
It is important to note that Glu- or Lys-Pg preincu-
bation had no effects on the activity of collagen­
stimulated platelets. These data indicate that Pg can 
affect NAD(P)H­dependent metabolic pathways of 
platelets, however, its effects significantly depends 
on the agonist used for platelet activation. Collagen 
is considered to be one of the most potent platelet 
activator and ROS formation inductor [23]. Possibly, 
reducing platelet metabolic activity observed in our 
experiment after collagen stimulation can be a result 
of oxidative burst induced by submaximal concen-
tration of agonist.  
Next, in order to verify if Pg can affect ago-
nist-induced redox signalling mechanisms, we used 
a redox­sensitive fluorescent dye (H2DCF-DA) to 
quantify intraplatelet ROS levels by flow cytometric 
assay. The platelets were selected on the basis of side 
scattering (SSC) and DCF­fluorescence (FL2). As 
shown in Fig. 2, the vast majority of washed resting 
platelets (Ctrl) (> 98%) were counted as DCF-posi-
tive events, indicating high percentage of viable and 
functionally active cells studied in ex vivo condi-
tions. This also means that during platelet isolation 
and resuspension a partial activation of these cells 
may occur. Our data corroborate with the earlier re-
port describing ability of platelets isolated by cen-
trifugation to produce O2•− [5]. Cell sorting allowed 
detecting two discrete subpopulations of living plate-
lets, which differ ultrastructurally and were distinct 
by the ability to produce ROS. 
The smaller subset (gate I, red) represents pre-
activated platelets, which have been earlier identi-
fied to expose increased P­selectin levels even in the 
samples of non-stimulated cells [15]. The number of 
such cells did not exceed ~9% of all the platelets ana-
lyzed (Fig. 2 and 3). The larger subset (gate II, blue) 
corresponds to the main platelet population (~90%), 
characterized by lower ROS production capability 
than the first platelet subset. 
Flow cytometry gave the possibility to analyze 
Pg and agonist-induced redistribution of platelets and 
to make a quantification of such changes. In response 
to treatment with Glu- or Lys-Pg, ROS production 
by the first population was slightly, but significantly 
(P < 0.05), increased (Fig. 3). However, the number 
of platelets inside the gates remained unchanged 
(Fig. 4). Elevated ROS production was demon strated 
in both populations of thrombin-treated platelets. 
The most intriguing observation was that Pg elici-
ted ROS generation in thrombin-stimu lated platelets 
(Lys-form to greater extent). Moreover, thrombin in-
creased the number of platelets in gate I up to 24%. 
In the case of collagen stimulation, dramatic 
redistribution of platelets into gate I and elevating 
DCF-positive signal were observed. Average num-
ber of highly activated platelets reached 29% after 
incubation with collagen. Surprisingly, pre-treatment 
of platelets with Pg resulted in increasing count of 
platelets in gate I followed by collagen activation 
(40 and 36% for Glu-Pg and Lys-Pg groups, respec-
tively).
Our previous investigations have demonstrated 
that Lys­Pg is able to affect the key platelet respon­
ses, including cytoskeletal rearrangement, secre-
tion, and aggregation [15-17], while Glu-Pg can be 
conside red as a co-stimulator of agonist-induced 
platelet secretion and procoagulant surface formation 
[24]. Nevertheless, the intimate molecular mecha-
nisms of such effects remain poorly understood. It 
can be assumed that Pg-induced alterations can be 
due to Pm formation on the platelet surface. Pm is 
capable of triggering signaling in various cell types, 
which depends on cellular binding via its lysine-
binding sites and its proteolytic activity [25]. In vitro 
and in vivo studies have demonstrated the ability of 
Pm to stimulate the production of cytokines, ROS, 
intracellular increase in Ca2+ and other mediators, 
thereby even contributing to cell death [26]. Recent-
ly, it has been demonstrated that direct effects of Pm 
on platelets, including the intracellular Ca2+ increase 
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Fig. 2. Effects of Glu- or Lys-plasminogen on intraplatelet ROS generation: representative flow cytometric dot 
plots and histograms of platelet subpopulations
and platelet aggregation, are mediated mainly by the 
low‐affinity thrombin receptor PAR4 [27]. On the 
other hand, truncation of PAR-1 at the C-terminal 
Pm-cleavage sites removes the N-terminal tethered 
ligand or preligand, thereby providing an effective 
pathway for PAR1 desensitization [28]. It has been 
suggested that PAR4 plays a major role in calcium 
signaling and the induction of sustained aggregation, 
while PAR1 shows a more prominent role in platelet 
secretion and synthesis. Coughlin [29] has described 
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Fig. 3. Effects of Glu- or Lys-plasminogen on intracellular ROS generation by resting and activated platelets 
expressed as DCF fluorescence intensities. Rest – resting (control) platelets, Thr – thrombin, Col – collagen; 
* P < 0.05 vs. Rest, # P < 0.05 vs. Thr
Fig. 4. redistribution of platelet subsets induced by Glu- or Lys-plasminogen. rest – resting (control) plate-
lets, Thr – thrombin, Col – collagen
that PAR-1 is a primary receptor mediating platelet 
apoptosis. Other studies have provided evidence that 
Pm/PAR1 axis is implicated in triggering apoptosis 
and excitotoxicity in neurons, astrocytes, and micro-
glia; Pm inhibitors have been found to be neuropro-
tective [30]. In the bloodstream, Pg circulates pre-
dominantly as a native protein (Glu-Pg). However, on 
the platelet surface Glu-Pg can be easily turned to a 
partially truncated form, or Lys-Pg. It should be kept 
in mind that the latter has an open conformation and 
is more readily converted into Pm by Pg activators 
[12, 13]. This fact could explain why Lys-Pg exhibits 
more pronounced effect to stimulate ROS generation 
than Glu-form, even if incubated alone with resting 
platelets.
Data obtained by cytometry assay indicate that 
modulating effects of Pg depends on the nature of 
agonist used for platelet activation. Changes in plate-
let sub­population profiles induced by Pg may reflect 
distinct signaling downstream events affected during 
Pg treatment. There are a few agonist-induced ac-
tivation pathways that produce ROS, including the 
collagen, thrombin, and arachidonic acid activation 
pathways. As expected, thrombin stimulation greatly 
enhances platelet redox signaling (Fig. 3). It is im-



















































































stimulated platelets pretreated with Pg appeared to 
be higher than that for platelets treated with throm-
bin only. Thrombin is a potent platelet activator 
and a GPIbα and PAR’s agonist [31]. Treatment of 
platelets with thrombin stimulates mitochondrial 
membrane potential depolarization and endogenous 
gene ration of hydrogen peroxide [4]. Upon activa-
tion, platelets undergo rapid changes in cell surface 
receptor expression that lead to altered adhesive 
proper ties and exposing additional binding sites for 
Pg molecules. Pm, which is converted from Pg on 
the platelet surface, can partially cleave and stimu-
late both thrombin-activated PAR-1 and -4 [27]. It 
can be hypothesized that Pm and thrombin act syn-
ergistically to stimulate intraplatelet production of 
reactive oxygen entities. The findings of Ghasemza-
deh [10] indicate that augmented ROS generation 
during storage might be relevant to down-regulation 
of platelet adhesive function. Therefore, overproduc-
tion of ROS in platelets co-exposed to Pg and throm-
bin may result in cell activity suppression due to the 
oxidative stress that is confirmed by the data of MTT 
assay (Fig. 1).
Platelet adherence to collagen is recognized 
as a critical initial event for generation of haemo-
static plug [32]. Collagen has been found to be the 
most potent ROS-generating agonist and inductor 
of apoptosis-like events in platelets [23]. It has been 
also shown that collagen-mediated GPVI-dependent 
intracellular oxidative burst in human platelets is 
maximally initiated within 2 min after stimulation 
[33]. Previous studies with Nox inhibitors have in-
dicated that NAD(P)H oxidase is responsible for the 
ROS production in GPVI-stimulated platelets [5, 8]. 
Flow cytometry assay indicates that collagen, in 
contrast to thrombin, dramatically abolished reduc-
tion of tetrazolium by platelet mitochondrial dehyd-
rogenases. It is possible that Pg/Pm and collagen 
synergistically activate platelets by PARs and GPVI, 
respectively, inducing oxidative damage to such hy-
per-stimulated cells. This observation can explain 
rapid loss of platelet activity in MTT-test during 
60 min period (Fig. 1). It is worth noting that several 
physiological stimuli that cause platelet activation at 
low concentrations propagate platelet apoptosis at 
higher concentrations. This is consistent with studies 
demonstrating that platelet activators increase mito-
chondrial membrane potential at low concentrations, 
whereas prolonged exposure to higher concentra-
tions induces the collapse of membrane potential 
[7]. In addition, the recent research of Whyte et al. 
[34] indicates that functional Pg pool accumulates 
on the platelet membrane following strong agonist 
stimulation under physiological flow conditions. Pg 
has been shown to bind directly to platelets, but pre-
dominantly with phosphatidylserine (PS)-exposing 
platelets with shortened survival, which are under-
went apoptosis [35]. Moreover, this sub-population 
of platelets displays an enhanced capacity to genera-
te Pm on their surface, which is thought to be in-
volved in modulating local fibrinolysis.
Conclusion. ROS have been demonstrated as 
critical signals regulating platelet activity, while 
their generation correlates with P-selectin expression 
and platelet aggregation, which are energy-consu-
ming processes. However, overproduction of ROS 
can harm platelet adhesive activity or cause apop-
tosis. In the present paper, we demonstrated for the 
first time that Pg is able to enhance ROS production 
in activated platelets and to reduce their viabili ty. 
Conside ring that the surface of platelets expose more 
binding sites for Pg when they are activated in the 
site of vessel injury, suppression of platelet activity 
by Pg (especially by Lys-form) may impact on the 
function of these cells in coagulation. Such dual tar-
geting/signaling can be potentially important in vivo, 
when significantly high concentrations of thrombin 
present close to a thrombus, and Pg may act restric-
ting further thrombogenesis when additional plate-
lets may not be needed. 
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Активні форми оксигену (АФО) є важливи-
ми сигнальними молекулами, які контролюють 
функціонування тромбоцитів, а їх продукція 
підсилюється під час тромбоцитарної актива-
ції. Модуляторні ефекти плазміногену (Pg) на 
утворення АФО тромбоцитами раніше не дослі-
джувалися. Метою цієї роботи було визначити 
здатність різних форм Pg впливати на метабо-
A. A. Tykhomyrov, D. D. Zhernosekov, m. m. Guzyk et al.
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лічну активність/виживаність тромбоцитів та 
утворення ними АФО в стані спокою і за умов 
активації. Тромбоцити, ізольовані із плазми до-
норів, преінкубували з Glu­ або Lys­Pg (1,2 µM) 
та активували тромбіном (1,0 од. NIH/мл) або 
колагеном (1,25 мг/мл). Загальну дегідрогеназну 
активність мітохондрій визначали за допомогою 
МТТ­тесту, протокову цитофлуориметрію з ви-
користанням зонду H2DCF­DA застосовували 
для вимірювання внутрішньоклітинних рівнів 
АФО. Встановлено, що Lys­Pg незначним чи-
ном пригнічує відновлення МТТ (P < 0,05 про-
ти контролю). Тромбін спричинював дворазове 
збільшення рівня метаболічної активності тром-
боцитів порівняно з інтактними клітинами. Од-
нак активація, індукована тромбіном, була менш 
вираженою у разі тромбоцитів, преінкубованих 
з Pg, причому Lys­Pg спричинював більший інгі-
бувальний ефект. На відміну від тромбіну кола-
ген значно пригнічував метаболічну активність 
тромбоцитів (на 60% від контрольної величини, 
P < 0,05). Glu­ та Lys­Pg не впливали на актив-
ність колагенстимульованих тромбоцитів у 
МТТ­тесті. Сортінг тромбоцитів за здатністю 
продукувати АФО виявив дві різні субпопуляції 
клітин. Зростання продукції АФО спостерігало-
ся за активації тромбоцитів як тромбіном, так і 
колагеном. Pg (Lys­форма більшою мірою) під-
силював внутрішньоклітинну генерацію АФО у 
тромбінстимульованих тромбоцитах. Показано, 
що посилення Pg генерації АФО, яке передує дії 
агоністів, може призводити до зниження їх жит-
тєздатності та функціональної активності. Це 
дослідження доповнює уявлення про можливі 
механізми впливу Pg на функціонування тром-
боцитів.
К л ю ч о в і  с л о в а: плазміноген, тромбо-
цити, активні форми оксигену (АФО), H2DCF-
DA, протокова цитофлуориметрія, МТТ­тест. 
плазминоген модулирует 
образование активных форм 
кислорода тромбоцитами 
человека
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Активные формы кислорода (АФК) являют-
ся важными сигнальными молекулами, которые 
контролируют функционирование тромбоци-
тов, а их продукция усиливается в ходе тромбо-
цитарной активации. Модуляторные эффекты 
плазминогена (Pg) на образование АФК тромбо-
цитами ранее не изучались. Целью представлен-
ной работы было определить влияние различ-
ных форм Pg на метаболическую активность/
выживание тромбоцитов и образование ими 
АФК в состоянии покоя и в условиях активации. 
Тромбоциты, изолированые из плазмы доноров, 
преинкубировали с Glu­ или Lys­Pg (1,2 µM) и ак-
тивировали тромбином (1,0 ед. NIH/мл) или кол-
лагеном (1,25 мг/мл). Общую дегидрогеназную 
активность митохондрий оценивали с помощью 
МТТ­теста, проточную цитофлуо риметрию с 
использованием зонда H2DCF­DA применяли 
для измерения внутриклеточных уровней АФК. 
Установлено, что Lys­Pg незначительным об-
разом угнетает восстановление МТТ (P < 0,05 
относительно контроля). Тромбин вызывал дву-
кратное усиление уровня метаболической актив-
ности тромбоцитов по сравнению с интактными 
клетками. Однако активация, индуцированная 
тромбином, была менее выраженной в случае 
тромбоцитов, преинкубированных с Pg, причем 
Lys­Pg обладал более сильным ингибирующим 
эффектом. В отличие от тромбина коллаген су-
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щественно угнетал метаболическую активность 
тромбоцитов (на 60% от контрольной величины, 
P < 0,05). Glu­ и Lys­Pg не влияли на активность 
в МТТ­тесте коллагенстимулированных тром-
боцитов. Сортинг тромбоцитов по способно-
сти продуцировать АФК выявил две различные 
популяции клеток. Усиление продукции АФК 
наблюдалось при активации тромбоцитов как 
тромбином, так и коллагеном. Pg (Lys­форма в 
большей степени) интенсифицировал внутри-
клеточную генерацию АФК в тромбинстимули-
рованных тромбоцитах. Показано, что усиление 
Pg продукции АФК, предшествующее действию 
агонистов, может приводить к снижению жиз-
неспособности и функциональной активности 
клеток. Данное исследование дополняет пред-
ставления о возможных механизмах влияния Pg 
на функционирование тромбоцитов.
К л ю ч е в ы е  с л о в а: плазминоген, тром-
боциты, активные формы кислорода (АФК), 
H2DCF­DA, проточная цитофлуориметрия, 
МТТ­тест.
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